Unadjusted | IPTW adjusted | ||||||
---|---|---|---|---|---|---|---|
Variable | Levels | O-ILE N = 69 | M-ILE N = 154 | p-value | O-ILE N = 68 | M-ILE N = 142 | p-value |
Clinical T-stage | 1/2 | 22 (31.9%) | 30 (19.5%) | 0.043 | 21.00% | 23.10% | 0.731 |
3 | 47 (68.1%) | 124 (80.5%) | 79.00% | 76.90% | |||
Clinical N-stage | N0 | 16 (23.2%) | 66 (42.9%) | 0.001 | 41.46% | 37.01% | 0.868 |
N1 | 50 (72.5%) | 71 (46.1%) | 51.38% | 56.05% | |||
N2 | 3 (4.3%) | 17 (11.0%) | 7.17% | 6.95% | |||
Histology | Squamous Cell Carcinoma | 3 (4.3%) | 11 (7.1%) | 0.426 | 3.07% | 7.26% | 0.166 |
Adenocarcinoma | 66 (95.7%) | 143 (92.9%) | 96.93% | 92.74% | |||
Pathologic T-stage | T0 | 19 (27.5%) | 41 (26.6%) | 0.703 | 18.89% | 27.22% | 0.674 |
T1a/T1b | 12 (17.4%) | 28 (18.2%) | 17.78% | 17.71% | |||
T2 | 11 (15.9%) | 34 (22.1%) | 24.09% | 22.50% | |||
T3 | 27 (39.1%) | 51 (33.1%) | 39.24% | 32.57% | |||
Pathologic N-Stage | N0/Nx | 43 (62.3%) | 99 (64.3%) | 0.399 | 60.83% | 66.18% | 0.394 |
N1 | 13 (18.8%) | 37 (24.0%) | 20.31% | 22.92% | |||
N2 | 7 (10.1%) | 12 (7.8%) | 10.22% | 7.87% | |||
N3 | 6 (8.7%) | 6 (3.9%) | 8.64% | 3.03% | |||
Differentiation | Moderate | 46 (66.7%) | 74 (48.1%) | 0.031 | 67.44% | 50.42% | 0.139 |
Poor | 21 (30.4%) | 69 (44.8%) | 28.77% | 42.68% | |||
Well | 2 (2.9%) | 11 (7.1%) | 3.79% | 6.90% | |||
Lymphovascular invasion | Yes | 14 (20.3%) | 42 (27.3%) | 0.266 | 20.04% | 27.24% | 0.309 |
Perineural invasion | Yes | 16 (23.2%) | 30 (19.5%) | 0.527 | 21.30% | 19.64% | 0.792 |
Signet ring cell features | Yes | 4 (5.8%) | 19 (12.3%) | 0.138 | 9.93% | 11.97% | 0.741 |
Tumor regression grade | Complete response | 18 (26.1%) | 38 (24.7%) | 0.043 | 18.60% | 25.58% | 0.274 |
Near complete response | 24 (34.8%) | 58 (37.7%) | 42.41% | 36.52% | |||
Partial response | 11 (15.9%) | 42 (27.3%) | 20.61% | 27.75% | |||
No response | 16 (23.2%) | 16 (10.4%) | 18.38% | 10.14% | |||
Lymph nodes removed | Median [IQR] | 18 [14–22] | 17 [14–21] | 0.956 | 16 [12–20] | 17 [13–21] | 0.822 |